Nefazodone therapy in patients with treatment-resistant or treatment- intolerant depression and high psychiatric comorbidity

Clinical Therapeutics

Volumn 21, Issue 4, 1999, Pages 733-740

  Sajatovic, Martha ^a,b,c   DiGiovanni, Sue ^a,b   Fuller, Matthew ^a,b   Belton, Joan ^a   DeVega, Eva ^a   Marqua, Sybille ^a,b   Liebling, David ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c ODMH Northcoast Behavioral Healthcare   (United States)

Author keywords

Antidepressant medication; Nefazodone; Posttraumatic stress disorder; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZATROPINE; BUSPIRONE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; FLUOXETINE; FLUPHENAZINE; LORAZEPAM; NEFAZODONE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DEPRESSION; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOTHERAPY; RATING SCALE; SOMNOLENCE; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 0033017741     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88324-1     Document Type: Article

References (26)

1. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry. 1997; 58(Suppl 6):32-39.
2. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: Progress and limitations. Psychiatr Ann. 1998;28:633-640.
3. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull. 1991;26:429-460.
4. Keller MB. Undertreatment of major depression. Psychopharmacol Bull. 1988;24: 75-80.
5. Guscott R, Grof P. The clinical meaning of refractory depression: A review for the clinician. Am J Psychiatry. 1991;148:695-704.
6. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
7. Nunes EV, Deliuannides D, Donovan S, McGrath PJ. The management of treatment resistance in depressed patients with substance use disorders. Psychiatr Clin North Am. 1996;19:311-327.
8. Hornig-Rohan M, Amsterdam JD. Clinical and biological correlates of treatment-resistant depression: An overview. Psychiatr Ann. 1994;24:220-227.
9. Nelson JC. Treatment of antidepressant nonresponders. Augmentation or switch? J Clin Psychiatry. 1998;59(Suppl 15):35-41.
10. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53:785-792.
11. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin re-uptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269-271.
12. Zajecka JM, Jeffriess H, Fawcett J.The efficacy of fluoxetine combined with a heterocyelic antidepressant in treatment-resistant depression: A retrospective analysis. J Clin Psychiatry. 1995;56:338-343.
13. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. Am J Psychiatry. 1994;151:1372-1374.
14. Jefferson JW. Drug interactions - friend or foe? J Clin Psychiatry. 1998;59(Suppl 4):37-47.
15. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry. 1994;55:234-241.
16. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: A placebo controlled trial. Br J Psychiatry. 1994;164:802-805.
17. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry. 1996;57(Suppl 2):31-38.
18. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry. 1996;57(Suppl 2):53-62.
19. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry: 1995; 56(Suppl 6):37-42.
20. Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry. 1996;57(Suppl 2):19-23.
21. Fuller M, Sajatovic M. Drug Information Handbook for Psychiatry. 1st ed. Cleveland, Ohio: Lexi-Comp., Inc., 1998.
22. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
23. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961:4:561-571.
24. Guy W. Clinical Global Inventory. In: Early Clinical Drug Evaluation Unit (ECDEU): Assessment Manual for Psychopharmacology (Revised). Washington, DC: US Department of Health, Education and Welfare; 1976.
25. Weiss KJ. Optimal management of anxiety in older patients. Drugs Aging. 1996; 9:191-201.
26. Hertzberg M, Feldman M, Beckman J, et al. Open trial of nefazodone treatment for post traumatic stress disorder. Presented at: New Clinical Drug Evaluation Unit (NCDEU) Program. May 28, 1997; Boca Raton, Fla.